Anthem Biosciences Reports Q1FY27 Results: Revenue Stands at ₹4,182 Mn; EBITDA Margin Reaches 39.6%
Bengaluru: Anthem Biosciences Limited, a technology-focused Contract Research, Development and Manufacturing Organization (CRDMO), announced its unaudited Consolidated Financial Results for the quarter ended June 30, 2026. The company reported Consolidated Revenue from Operations at ₹4,182 Mn, while EBITDA was ₹1,755 Mn, translating to an EBITDA margin of 39.6%. Profit After Tax (PAT) was recorded at ₹1,199 Mn, reflecting a PAT margin of 27.1%.The company's performance across key business segments showed the following structure:Particulars (₹ Mn)Q1FY27Q1FY26YoY ChangeRevenue from Operations4,1825,402-22.6%CRDMO...